Amneal Pharmaceuticals, Inc. $AMRX Shares Bought by Globeflex Capital L P

Globeflex Capital L P increased its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 324.1% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 136,505 shares of the company’s stock after buying an additional 104,321 shares during the period. Globeflex Capital L P’s holdings in Amneal Pharmaceuticals were worth $1,720,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Comerica Bank increased its holdings in Amneal Pharmaceuticals by 186.7% in the 3rd quarter. Comerica Bank now owns 3,005 shares of the company’s stock worth $30,000 after buying an additional 1,957 shares during the period. Spire Wealth Management increased its holdings in Amneal Pharmaceuticals by 66.6% in the 4th quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock worth $32,000 after buying an additional 1,023 shares during the period. Focus Partners Wealth acquired a new position in Amneal Pharmaceuticals in the 3rd quarter worth approximately $42,000. Advisory Services Network LLC acquired a new position in Amneal Pharmaceuticals in the 3rd quarter worth approximately $50,000. Finally, Strs Ohio acquired a new position in Amneal Pharmaceuticals in the 4th quarter worth approximately $52,000. Institutional investors and hedge funds own 31.82% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on AMRX. Truist Financial increased their price target on shares of Amneal Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. UBS Group began coverage on shares of Amneal Pharmaceuticals in a research note on Friday, April 17th. They issued a “buy” rating and a $19.00 price target on the stock. Barclays lifted their price target on shares of Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research note on Wednesday, May 20th. Weiss Ratings cut shares of Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, May 26th. Finally, Zacks Research cut shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 6th. Six research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $15.17.

Insider Activity at Amneal Pharmaceuticals

In other news, Director Deborah M. Autor sold 34,819 shares of Amneal Pharmaceuticals stock in a transaction on Monday, May 11th. The stock was sold at an average price of $12.94, for a total transaction of $450,557.86. Following the transaction, the director owned 93,660 shares in the company, valued at $1,211,960.40. The trade was a 27.10% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 17.30% of the stock is currently owned by corporate insiders.

Amneal Pharmaceuticals Stock Performance

Amneal Pharmaceuticals stock opened at $13.52 on Friday. The company’s fifty day moving average price is $12.70 and its 200 day moving average price is $12.96. Amneal Pharmaceuticals, Inc. has a 1 year low of $7.07 and a 1 year high of $15.42. The stock has a market capitalization of $4.31 billion, a P/E ratio of 35.58 and a beta of 1.30.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.27 earnings per share for the quarter. Amneal Pharmaceuticals had a negative return on equity of 313.96% and a net margin of 4.01%.The company had revenue of $722.52 million for the quarter. Sell-side analysts predict that Amneal Pharmaceuticals, Inc. will post 0.92 EPS for the current year.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.